Research programme: small molecule therapeutics - EloracAlternative Names: Small molecules Heprotect™
Latest Information Update: 03 Mar 2017
At a glance
- Originator Gideon Pharmaceuticals
- Developer Elorac
- Mechanism of Action 14-alpha demethylase inhibitors; Cyclo-oxygenase 2 inhibitors; Retinoic acid receptor agonists; Tetrahydrofolate dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Inflammation; Mycoses; Pain; Psoriasis